Key result
AML shows non-significant trend toward higher post-PCI mortality than ALL in acute leukemia.
Why the study?
Patients with acute leukemia undergoing PCI represent a high-risk group with unclear in-hospital mortality rates, predictors, and complication profiles.
Cohort (n=1,425)
Yes
Odds Ratio: 3.23
Absolute Event Rate: 14.1% vs 4.6%
p-value: p=0.080
Patients with acute leukemia undergoing PCI experience substantial in-hospital mortality (11.9%) and an extremely high rate of acute kidney injury (87.7%), emphasizing the need for targeted nephroprotective strategies and specialized cardio-oncology care.
Age signals higher in-hospital mortality in acute leukemia; leaves open whether age-stratified protocols improve outcomes in prospective cohorts.
Background Patients with acute leukemia requiring percutaneous coronary intervention (PCI) represent a high-risk population at the intersection of oncologic and cardiovascular disease. This study aimed to determine in-hospital mortality rates, identify mortality predictors, and characterize complications in acute leukemia patients undergoing PCI. Methods Retrospective cohort analysis using the National Inpatient Sample (2016-2022) identified adult patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who underwent PCI. Multivariable logistic regression identified independent mortality predictors after adjusting for demographics, comorbidities, leukemia subtype, and hospital factors. Primary outcome was in-hospital mortality; secondary outcomes included acute kidney injury, major bleeding, blood transfusion, and stroke. Results Among 285 admissions representing 1,425 patients nationwide (22.8% ALL, 77.2% AML; mean age 67 years), overall in-hospital mortality was 11.9% (95% CI: 8.7%-16.2%). Mortality differed by subtype: 4.6% in ALL versus 14.1% in AML (p=0.038). Advancing age was an independent mortality predictor (adjusted OR 1.055 per year, 95% CI: 1.008-1.104, p=0.022). AML versus ALL demonstrated a trend toward increased risk (adjusted OR 3.23, p=0.080). Acute kidney injury was the most prevalent complication at 87.7%. Non-survivors incurred significantly higher hospital charges ($222,639 vs. $147,959; p=0.013). Conclusions Acute leukemia patients undergoing PCI experience substantial in-hospital mortality of approximately 12%, with AML patients at significantly higher risk than ALL patients. Age is the primary independent mortality predictor. The exceptionally high acute kidney injury rate highlights the urgent need for nephroprotective strategies and intensive multidisciplinary cardio-oncology care.
No takes yet. Share an insight, caveat, or question.
Bolad et al. (2026) conducted a cohort in Acute leukemia requiring percutaneous coronary intervention (n=1,425). Acute myeloid leukemia (AML) vs. Acute lymphoblastic leukemia (ALL) was evaluated on In-hospital mortality (adjusted OR 3.23, p=0.080). Among acute leukemia patients undergoing PCI, overall in-hospital mortality was 11.9%, with AML patients demonstrating a trend toward higher mortality than ALL patients (14.1% vs 4.6%; adjusted OR 3.23; p=0.080).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: